Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities

Future progress in endometrial cancer requires continued focus on several key areas. Biomarker development remains a high priority, especially for identifying which patients within the pMMR population are most likely to benefit from immunotherapy or combination strategies. Although multiple potential markers exist, none fully capture response patterns across all subgroups.As more therapies emerge, optimizing treatment sequencing becomes increasingly important. Clinicians must determine how best to integrate immune checkpoint inhibitors, targeted agents and future antibody drug conjugates into long term care. Survivorship is also growing in importance as more patients achieve durable benefit. Long term toxicity management, quality of life and prevention strategies for high risk disease will be central to patient centered care. These priorities reflect a field that is rapidly advancing beyond its historical limitations toward more precise and sustainable treatment.